Drug-free research in schizophrenia: An overview of the controversy

IRB Ethics and Human Research

Volumn 18, Issue 1, 1996, Pages 1-5

  Appelbaum, Paul S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PSYCHOTROPIC AGENT;

ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; DRUG TOXICITY; EVALUATION; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; MENTAL HEALTH THERAPIES; MENTAL PATIENT; METHODOLOGY; OFFICE FOR PROTECTION FROM RESEARCH RISKS; PERSONNEL; PHYSICIAN; RANDOMIZATION; RESEARCH SUBJECT; RISK; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT WITHDRAWAL; UCLA SCHOOL OF MEDICINE; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; MENTAL HEALTH THERAPIES; OFFICE FOR PROTECTION FROM RESEARCH RISKS; UCLA SCHOOL OF MEDICINE;

DRUG TOXICITY; EVALUATION STUDIES; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; LOS ANGELES; MENTALLY ILL PERSONS; PHYSICIANS; PLACEBOS; PSYCHOTROPIC DRUGS; RANDOM ALLOCATION; RESEARCH DESIGN; RESEARCH PERSONNEL; RESEARCH SUBJECTS; RISK; RISK ASSESSMENT; SCHIZOPHRENIA; UNITED STATES; WITHHOLDING TREATMENT;

EID: 0029693310     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: 10.2307/3563910     Document Type: Review

References (32)

1. The description of the UCLA protocols is taken from: Office of Protection from Research Risks: Evaluation of Human Subject Protections in Schizophrenia Research Conducted by the University of California Los Angeles, 11 May 1994.
2. Hilts, P: Agency faults a UCLA study for suffering of mental patients. New York Times, 10 March 1994.
3. Willwerth, J: Madness in fine print. Time, 7 November 1994.
4. Hilts, P: House panel told of more tests done without consent. New York Times, 24 May 1994.
5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disordes, 4th ed. (DSM-IV). Washington, D.C.: American Psychiatric Association, 1994.
6. Janicak, PG, Davis, JM, Preskorn, SH, and Ayd, FJ: Principles and Practice of Psychopharmacotherapy. Baltimore, Md.: Williams and Wilkins, 1993.
7. Meltzer, HY, Cola, P, Way, L, et al.: Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry 1993; 150:1630-38.
8. Levinson, DF, and Simpson, GM: Antipsychotic drug side effects, in Psychiatry Update: American Psychiatric Association Annual Review, ed. RE Hales and AJ Frances, vol. 6. Washington, D.C.: American Psychiatric Press, 1987, pp. 704-23.
9. American Psychiatric Association: Tardive Dyskinesia: A Task Force Report. Washington, D.C.: American Psychiatric Association, 1992.
10. Carpenter, WT, Schooler, NR, and Kane, JM: The ethics and rationale of medication-free research in schizophrenia. (Unpublished manuscript.)
11. Gilbert, PL, Harris, MJ, McAdams, A, and Jeste, DV: Neuroleptic withdrawal in schizophrenia: A review of the literature. Archives of General Psychiatry 1995; 52:173-88.
12. Baldessarini, RJ, and Viguera, AC: Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry 1995; 52:189-91.
13. Wyatt, RJ: Risks of withdrawing antipsychotic medications. Archives of General Psychiatry 1995; 52:205-8.
14. Wyatt, RJ: Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 1991; 17:325-51.
15. Carpenter, WT, and Tamminga, CA: Why neuroleptic withdrawal in schizophrenia? Archives of General Psychiatry 1995; 52:192-93.
16. Shamoo, A: Presentation at the annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1994.
17. The Nuremberg Code, in Ethics in Medicine: Historical Perspectives and Contemporary Concerns, ed. SJ Reiser, AJ Dyck, and WJ Curran. Cambridge, Mass.: MIT Press, 1977, pp. 272-73.
18. National Alliance for the Mentally Ill: Policies on Strengthened Standards for Protection of Individuals with Severe Mental Illnesses Who Participate as Human Subjects in Research Arlington, Va.: National Alliance for the Mentally Ill, February 1995.
19. Rothman, KJ, and Michels, KB: The continuing unethical use of placebo controls. NEJM 1994; 331:394-98.
20. The use of placebo controls (Letters). NEJM 1995; 332:60-62.
21. World Medical Association: Declaration of Helsinki, Encyclopedia of Bioethics, ed. WT Reich. New York: Simon & Shuster, 1995, pp. 2765-67.
22. Levine, RJ: Uncertainty in clinical research. Law, Medicine & Health Care 1988; 16:174-82.
23. Streiner, DL: The ethics of placebo-controlled trials (editorial). Canadian Journal of Psychiatry 1995; 40:165-66.
24. Makuch, RW, and Johnson MF: Dilemmas in the use of active control groups ta clinical research. IRB 1989; 11(1):1-5.
25. Addington, D: The use of placebos in clinical trials for acute schizophrenia. Canadian Journal of Psychiatry 1995; 40:171-76.
26. Levine, RJ: Ethics and Regulation of Clinical Research, 2nd ed. Baltimore, Md.: Urban & Schwarzenburg, 1986, p. 267.
27. Katz, J: Human experimentation and human rights. St. Louis University Law Journal 1993; 38:7-54.
28. Appelbaum, PS, Roth, LH, and Lidz, CW: False hopes and best data: consent to research and the therapeutic misconception. Hastings Center Report 1987; 17(2):20-24.
29. Stanley, B, Stanley, M, Lautin, A, et al.: Preliminary findings on psychiatric patients as research participants: A population at risk? American Journal of Psychiatry 1981; 138:669-71.
30. Grisso, T, and Appelbaum, PS: The MacArthur Treatment Competence Study, III: Abilities of patients to consent to psychiatric and medical treatments. Law and Human Behavior 1995; 19:149-74.
31. Appelbaum, PS: Patients' competence to consent to neurobiological research. Accountability in Research 1996; 4:241-51.
32. Carpenter, WT, Bartko, JJ, Carpenter, CL, and Strauss, JS: Another view of schizophrenia subtypes: A report from the International Pilot Study of Schizophrenia. Archives of General Psychiatry 1976; 33:508-16.